<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-57164" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chlorthalidone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerndt</surname>
            <given-names>Connor C.</given-names>
          </name>
          <aff>Spectrum Health/Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Jayesh B.</given-names>
          </name>
          <aff>University of Iowa Hospitals and Clinics</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Kerndt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayesh Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-57164.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Chlorthalidone is a thiazide-like diuretic used to treat hypertension. This activity&#x000a0;discusses&#x000a0;chlorthalidone's&#x000a0;indications and contraindications&#x000a0;when managing hypertension, edema, and calcium nephrolithiasis.&#x000a0;Additionally, its mechanism of action, adverse event profile, pharmacokinetics, monitoring, and clinical toxicology are discussed. By exploring these aspects, healthcare professionals understand chlorthalidone's pharmacology, empowering them to tailor treatment plans to individual patient needs. By emphasizing the crucial role of the interprofessional healthcare team, this initiative equips participants with essential knowledge and tools to optimize patient care during chlorthalidone administration, thereby improving patient outcomes through evidence-based medicine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of chlorthalidone.</p></list-item><list-item><p>Assess the potential adverse effects of chlorthalidone.</p></list-item><list-item><p>Determine the&#x000a0;appropriate monitoring for patients on therapy with chlorthalidone.</p></list-item><list-item><p>Implement&#x000a0;interprofessional team strategies for improving care coordination and communication to advance proper chlorthalidone administration and verify medication allergies.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=57164&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=57164">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-57164.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Chlorthalidone is a thiazide-like sulfonamide-derived diuretic that has been FDA-approved since 1960 to manage hypertension.<xref ref-type="bibr" rid="article-57164.r1">[1]</xref>&#x000a0;Chlorthalidone is a first-line agent for the treatment of hypertension.<xref ref-type="bibr" rid="article-57164.r2">[2]</xref>&#x000a0;This medication is utilized both&#x000a0;as an isolated agent and in combination with other antihypertensive drugs, including &#x003b2;-blockers or clonidine.&#x000a0;Chlorthalidone is&#x000a0;also used to treat edema.<xref ref-type="bibr" rid="article-57164.r3">[3]</xref> The utility&#x000a0;for edema comes in multiple settings, including congestive heart failure, hepatic cirrhosis, corticosteroid therapy, as well as renal dysfunction, including chronic renal failure, nephrotic syndrome, and acute glomerular nephritis.<xref ref-type="bibr" rid="article-57164.r3">[3]</xref>&#x000a0;</p>
        <p>Chlorthalidone was&#x000a0;first used as an antihypertensive agent and effectively manages blood pressure by decreasing intravascular volume through promoted diuresis. Per the 2017 guideline for the prevention, detection, evaluation, and management of high blood pressure, chlorthalidone can be used as a first-line age in the setting of hypertension when there are no contraindications or contributory comorbidities.<xref ref-type="bibr" rid="article-57164.r4">[4]</xref>&#x000a0;However, patients with cerebrovascular disease, advanced chronic kidney disease, diabetes, and heart failure treatment would preferably receive therapy with angiotensin-converting enzyme-inhibiting medication (ACE-I). These guidelines suggest that dihydropyridine calcium channel blockers and thiazide-like diuretics are the preferred agents without comorbidities because of better cardiovascular outcomes, specifically the reduced risk of heart failure and cerebral vascular accident.<xref ref-type="bibr" rid="article-57164.r5">[5]</xref></p>
        <p>The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack) trial compared other first-line antihypertensives such as calcium channel blockers and angiotensin-converting-enzyme-inhibitors (ACE-I) against chlorthalidone.&#x000a0;The trial concluded that thiazide-like diuretics should be considered in the first-line treatment in&#x000a0;patients with hypertension as chlorthalidone had less association with stroke than ACE-I and less association with heart failure compared to calcium channel blockers. The results of this study were attributed to the earlier and more significant decrease in blood pressure, specifically systolic, from chlorthalidone compared to lisinopril and amlodipine.<xref ref-type="bibr" rid="article-57164.r5">[5]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Chlorthalidone helps treat calcium nephrolithiasis, M&#x000e9;ni&#x000e8;re disease, and diabetes insipidus, although it does not have FDA approval for these indications.<xref ref-type="bibr" rid="article-57164.r6">[6]</xref><xref ref-type="bibr" rid="article-57164.r7">[7]</xref><xref ref-type="bibr" rid="article-57164.r8">[8]</xref><xref ref-type="bibr" rid="article-57164.r7">[7]</xref>&#x000a0;Chlorthalidone&#x000a0;treats these&#x000a0;conditions by antagonizing the sodium chloride co-transporter in the distal convoluted tubule (DCT) in the loop of Henle.<xref ref-type="bibr" rid="article-57164.r9">[9]</xref>&#x000a0;Per the American Urological Association (AUA) guidelines, thiazide diuretics or chlorthalidone are recommended in patients with&#x000a0;high or relatively high urine calcium levels and experiencing recurrent calcium stones.<xref ref-type="bibr" rid="article-57164.r10">[10]</xref></p>
        <p>
<bold>Thiazide-like Medication Versus Thiazide-type Diuretics</bold>
</p>
        <p>Thiazide-type medications, most commonly hydrochlorothiazide (HCTZ), have been around longer than thiazide-like antihypertensives and were previously utilized more substantially. However, multiple studies have shown a preference for thiazide-like medications over their original counterparts. A 2015 systematic review showed that&#x000a0;chlorthalidone alleviated hypertensive burden by about 5.1 mm Hg of systolic blood pressure than HCTZ, finding chlorthalidone more potent than HCTZ.<xref ref-type="bibr" rid="article-57164.r11">[11]</xref>&#x000a0;</p>
        <p>In addition to potency, studies have demonstrated that chlorthalidone holds a longer duration of action than HCTZ, 24 hours with chlorthalidone versus 6&#x000a0;to 12 hours with HCTZ. This increased duration of action allows for increased flexibility in dosing.<xref ref-type="bibr" rid="article-57164.r11">[11]</xref> A study has shown that as a result of this longer duration of action, chlorthalidone is 1.5&#x000a0;to 2.0 times more efficacious at lowering systolic blood pressure than HCTZ (comparative antihypertensive effects between hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure).<xref ref-type="bibr" rid="article-57164.r12">[12]</xref></p>
        <p>
<bold>Cardiovascular Outcomes</bold>
</p>
        <p>When considering antihypertensive medications, the effect on cardiovascular outcomes is of the highest concern. The ALLHAT trial showed a decreased risk of heart failure exacerbation&#x000a0;and cerebral vascular accidents compared to amlodipine and lisinopril, respectively.<xref ref-type="bibr" rid="article-57164.r5">[5]</xref><xref ref-type="bibr" rid="article-57164.r13">[13]</xref> Additionally, a 2012 meta-analysis of&#x000a0;over 100,000 patients concluded that chlorthalidone and thiazide-like diuretics lowered the risk of heart failure by 21% and cardiovascular events by 12%. In comparison, thiazide-type HCTZ did not show improved outcomes compared to placebo.<xref ref-type="bibr" rid="article-57164.r5">[5]</xref></p>
      </sec>
      <sec id="article-57164.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Chlorthalidone&#x000a0;exerts its therapeutic action by antagonizing sodium-chloride symporter in the distal convoluted tubule of the nephron.&#x000a0;This drug is similar to a thiazide diuretic in its mechanism of action, although it has a mildly altered chemical structure. Both thiazide and thiazide-like diuretics contain a sulfonamide group that also works to inhibit carbonic anhydrase and its antagonistic action at the distal convoluted tubule.<xref ref-type="bibr" rid="article-57164.r11">[11]</xref></p>
        <p>Chlorthalidone inhibits sodium reabsorption at the level of the distal convoluted tubule and thus chloride via inhibition of the Na-Cl&#x000a0;symporter. By removing sodium reabsorption at this location, the distal convoluted tubule of the nephron retains a higher sodium content. This lack of reabsorption alters the osmotic gradient and shifts fluid distribution from the outside to the inside of the tubule. The increased osmotic load from its elevated sodium concentration leads to elevated intratubular volume, thus promoting its diuretic effect. The&#x000a0;increased elimination of sodium and extracellular fluid leads to a reduction in intravascular water and solute concentration.&#x000a0;Reduction of&#x000a0;the intravascular volume and osmotic gradient decreases hydrostatic pressure, ultimately leading to a clinically significant decrease in blood pressure.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Chlorthalidone typically begins to exert its therapeutic effects within 3 hours of administration, with peak plasma concentrations achieved 2 to 6 hours after the dose.</p>
        <p><bold>Distribution:</bold> Chlorthalidone exhibits high protein binding, predominantly to albumin, owing to its affinity for erythrocyte carbonic anhydrase.</p>
        <p><bold>Metabolism:</bold> Chlorthalidone undergoes partial hepatic metabolism.</p>
        <p><bold>Excretion:</bold> Renal excretion plays a pivotal role in eliminating chlorthalidone from the body, with the major portion excreted unchanged via the kidneys.&#x000a0;This drug's elimination half-life ranges from 45 to 60 hours, contributing to its sustained duration of action, which typically lasts between 48 to 72 hours.<xref ref-type="bibr" rid="article-57164.r14">[14]</xref></p>
      </sec>
      <sec id="article-57164.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Chlorthalidone&#x000a0;is available solely as an oral medication.&#x000a0;The fixed-dose combination of atenolol/chlorthalidone, azilsartan/chlorthalidone, and clonidine/chlorthalidone is also available.<xref ref-type="bibr" rid="article-57164.r15">[15]</xref></p>
        <p>
<bold>Available Strengths</bold>
</p>
        <p>Chlorthalidone is available in 15 mg, 25 mg, and 50 mg tablets.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Dosing regimens vary depending on clinical indication. For the treatment of heart failure, guidelines recommend starting at 12.5 mg or 25 mg daily and titrating up to 100 mg daily as necessary. For generalized edema, dosing begins with 50&#x000a0;to 100 mg daily and can be titrated to a maximum of 200 mg daily. As outlined below, chlorthalidone can&#x000a0;also be utilized to manage calcium nephrolithiasis, which is generalized administered at 25 mg daily.</p>
        <p>Hypertension: starting&#x000a0;dose of 12.5 to 25 mg daily, maximum dose of 100 mg daily (ACC/AHA)&#x000a0;<xref ref-type="bibr" rid="article-57164.r16">[16]</xref></p>
        <p>Heart failure: starting&#x000a0;dose of 12.5 mg or 25 mg daily, maximum dose of 100 mg daily (ACC/AHA/HFSA)&#x000a0;<xref ref-type="bibr" rid="article-57164.r17">[17]</xref></p>
        <p>Generalized edema: starting&#x000a0;dose of 12.5 to 25 mg orally once to twice daily, maximum dose of 100 mg daily (ACC Expert Consensus)<xref ref-type="bibr" rid="article-57164.r18">[18]</xref></p>
        <p>Calcium nephrolithiasis (off-label): 25 mg daily</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No dosage adjustments for chlorthalidone are provided in the product&#x000a0;labeling; use caution.&#x000a0;</p>
        <p><bold>Renal impairment:</bold> According to the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines, thiazide diuretics lose efficacy in diuresis and lower blood pressure as the glomerular filtration rate (GFR) worsens. However, chlorthalidone remains effective at a GFR &#x0003c;30 mL/min/1.73 m&#x000b2;.<xref ref-type="bibr" rid="article-57164.r19">[19]</xref>&#x000a0;In a double-blind, randomized, placebo-controlled trial among patients with stage 4 chronic kidney disease (eGFR 15 to 30 mL/min/1.73 m&#x000b2;) and uncontrolled hypertension, chlorthalidone therapy significantly improved blood pressure control compared to placebo at 12 weeks.<xref ref-type="bibr" rid="article-57164.r20">[20]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;There is insufficient research to check teratogenicity, but&#x000a0;chlorthalidone&#x000a0;should be used only during pregnancy if&#x000a0;absolutely necessary.&#x000a0;Observational studies suggest that chlorthalidone use in pregnancy does not significantly increase the risk of major congenital disabilities or miscarriage. However, thiazide diuretics, including chlorthalidone, have been associated with adverse fetal outcomes such as jaundice, thrombocytopenia, hypoglycemia, and electrolyte imbalances. Consequently, chlorthalidone is not the preferred first-line treatment for hypertension in pregnancy. While chlorthalidone/thiazides do not prevent or alter the course of pre-eclampsia, they should not be the primary therapy for hypertension during pregnancy.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;The concentration of chlorthalidone in breast milk is relatively low; however, the drug's prolonged clearance kinetics can result in its accumulation in newborns, particularly in premature infants. Additionally, chlorthalidone's pharmacological properties may inhibit lactation. Therefore, an alternative medication may be considered to minimize potential risks associated with infant exposure to chlorthalidone via breast milk.<xref ref-type="bibr" rid="article-57164.r21">[21]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and efficacy of chlorthalidone in pediatric populations have not been conclusively established.&#x000a0;As per the American Academy of Pediatrics (AAP), the initial recommended dose of chlorthalidone is 0.3 mg/kg, with a maximum daily dose of 2 mg/kg (or 50 mg per day).<xref ref-type="bibr" rid="article-57164.r22">[22]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>The patient's age is also a consideration when determining the appropriate chlorthalidone dosage. Lower initial doses, typically ranging from 6.25 mg to 12.5 mg daily, are recommended, with gradual titration as needed.&#x000a0;Diuretic medications, such as chlorthalidone, a Beers criteria medication, should be used cautiously.<xref ref-type="bibr" rid="article-57164.r23">[23]</xref></p>
      </sec>
      <sec id="article-57164.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Significant adverse effects are electrolyte derangement (hypokalemia, hyponatremia, etc), hypersensitivity reaction, and precipitation of acute gout attacks. The adverse effects of chlorthalidone&#x000a0;involve&#x000a0;most organ systems to differing degrees and manifestations. Of significance, electrolyte derangement is a commonly reported adverse effect of this medication, which results from&#x000a0;increased diuresis and altering of nephron physiology. Most commonly, chlorthalidone causes hypokalemia, but it may also cause hyponatremia or hypochloremia.&#x000a0;These known derangements&#x000a0;make monitoring serum electrolytes essential for patients receiving&#x000a0;chlorthalidone periodically throughout hypertensive management.&#x000a0;</p>
        <p>
<bold>Reported Adverse Effects (per the Food and Drug Administration):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal&#x000a0;adverse effects: anorexia, gastritis, nausea, emesis, cramping, loose stools, constipation, and pancreatitis&#x000a0;<xref ref-type="bibr" rid="article-57164.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Neurologic&#x000a0;reactions: paresthesias, dizziness, and headaches</p>
          </list-item>
          <list-item>
            <p>Hematologic reactions: aplastic anemia, leukopenia, agranulocytosis, and thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Cardiovascular reaction: orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Dermatologic&#x000a0;reactions: purpura, photosensitivity, rash, urticaria, necrotizing angiitis (cutaneous vasculitis), Lyell syndrome (toxic epidermal necrolysis), pseudoporphyria&#x000a0;<xref ref-type="bibr" rid="article-57164.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Other adverse reactions&#x000a0;include hyperglycemia, glycosuria, muscle spasm, weakness, restlessness, impotence, and hyperuricemia.<xref ref-type="bibr" rid="article-57164.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Digitalis: Medications like digitalis can influence serum electrolyte levels, potentially leading to warning signs such as dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscle fatigue, low blood pressure, decreased urine output, rapid heart rate, and gastrointestinal issues like nausea and vomiting.</p>
          </list-item>
          <list-item>
            <p>Insulin and oral hypoglycemic agents: Chlorthalidone therapy may affect insulin needs in&#x000a0;patients with diabetes, potentially necessitating adjustments in insulin dosage or requirements for higher doses of oral hypoglycemic agents. Additionally, latent diabetes may become apparent during treatment with chlorthalidone.</p>
          </list-item>
          <list-item>
            <p>Tubocurarine: Chlorthalidone and similar drugs can increase sensitivity to tubocurarine, affecting its action.</p>
          </list-item>
          <list-item>
            <p>Norepinephrine: Chlorthalidone may diminish arteries' responsiveness to norepinephrine, although the effect is not significant enough to render norepinephrine ineffective for therapeutic use.</p>
          </list-item>
          <list-item>
            <p>Lithium: Close monitoring of lithium levels is imperative in individuals undergoing lithium treatment due to the potential of diuretics such as chlorthalidone to diminish lithium excretion, consequently triggering lithium toxicity.<xref ref-type="bibr" rid="article-57164.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57164.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to chlorthalidone</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to the sulfonamides-derived&#x000a0;medications</p>
          </list-item>
          <list-item>
            <p>Anuria</p>
          </list-item>
        </list>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Significant electrolyte derangement (severe hypokalemia, severe hyponatremia)</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Older adult&#x000a0;population (due to risk of hyponatremia)</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Hypercalcemia</p>
          </list-item>
          <list-item>
            <p>Severe hyperuricemia or gout&#x000a0;<xref ref-type="bibr" rid="article-57164.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>A recent study investigated the effects of potassium magnesium citrate (KMgCit) versus potassium chloride (KCl) supplementation during chlorthalidone therapy for hypertension. The primary goal of this study was to evaluate changes in metabolic parameters. The study found that chlorthalidone alone increased fasting plasma glucose levels and reduced serum potassium, magnesium, and urinary citrate excretion. However, supplementation with KMgCit attenuated the rise in fasting plasma glucose compared to KCl. These findings suggest that KMgCit may be more effective than KCl in preventing chlorthalidone-induced hyperglycemia, potentially enhancing tolerability and cardiovascular safety.<xref ref-type="bibr" rid="article-57164.r28">[28]</xref></p>
      </sec>
      <sec id="article-57164.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The following items require periodic monitoring when the patients take chlorthalidone.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Serum electrolytes</bold>: Serum sodium, potassium, chloride, and calcium levels should be monitored.<xref ref-type="bibr" rid="article-57164.r29">[29]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Fluid status and blood pressure</bold>: All patients taking chlorthalidone require observation for dryness of mouth, thirst, lethargy, hypotension, oliguria, tachycardia, palpitations, and gastrointestinal disturbances, such as nausea and vomiting. Chlorthalidone is a diuretic, so an inappropriately high dose can cause severe volume depletion.</p>
          </list-item>
          <list-item>
            <p><bold>Magnesium level</bold>: It can increase the urinary excretion of magnesium and may result in hypomagnesemia.</p>
          </list-item>
          <list-item>
            <p><bold>Uric acid level</bold>: Hyperuricemia may occur, or frank gout may be precipitated in certain patients receiving chlorthalidone.</p>
          </list-item>
          <list-item>
            <p><bold>Serum glucose level:</bold>&#x000a0;Serum glucose may increase with chronic use.&#x000a0;</p>
          </list-item>
        </list>
        <p>There is insufficient research on teratogenicity, but&#x000a0;chlorthalidone&#x000a0;should be used during pregnancy only if necessary.</p>
      </sec>
      <sec id="article-57164.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Dizziness due to severe hypotension</p>
          </list-item>
          <list-item>
            <p>Electrolyte disturbances such as hypokalemia, hyponatremia, and hypomagnesemia</p>
          </list-item>
        </list>
        <p>
<bold>Management&#x000a0;of acute overdosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No specific antidote is available</p>
          </list-item>
          <list-item>
            <p>Gastric lavage</p>
          </list-item>
          <list-item>
            <p>Supportive management includes intravenous dextrose or normal saline for hypotension and intravenous potassium chloride for severe hypokalemia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57164.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As a sulfonamide-derived medication, the clinician must review relevant allergies when prescribing chlorthalidone. An interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialists, nurse practitioners, physician assistants, nurses, and pharmacists, can help to maintain updated allergies. A review of allergies can start upon reception by asking patients to review their previous chart and update relevant sections, including allergies. While in a hospital setting, it can be prompted before administration by the clinician. In a pharmacy setting, the pharmacist can inquire before dispensing chlorthalidone. Additionally, EMR software now allows an additional barrier with risk-advisory when prescribing medication to which patients are allergic.<xref ref-type="bibr" rid="article-57164.r30">[30]</xref>&#x000a0;</p>
        <p>In addition to allergies, clinicians and pharmacists are responsible for counseling the patient, verifying dosing, and monitoring for adverse events. Pharmacists must also perform medication reconciliation to preclude any possible drug-drug interactions and notify the other interprofessional healthcare team members when concerns arise.</p>
        <p>Updating the type of adverse reaction occurring with the allergy is vital to avoid and characterize the true allergy. Deciphering whether a true allergy or previous adverse effects&#x000a0;from a medication is crucial as it changes therapeutic options for the patient.<xref ref-type="bibr" rid="article-57164.r30">[30]</xref>&#x000a0;The interprofessional paradigm contributes to positive patient outcomes when using chlorthalidone.</p>
      </sec>
      <sec id="article-57164.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=57164&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=57164">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/57164/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=57164">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-57164.s11">
        <title>References</title>
        <ref id="article-57164.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HOLLANDER</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>WILKINS</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Chlorothiazide: a new type of drug for the treatment of arterial hypertension.</article-title>
            <source>BMQ</source>
            <year>1957</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>69</fpage>
            <page-range>69-75</page-range>
            <pub-id pub-id-type="pmid">13471453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanikgaivasan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Letter - Diuretics in primary hypertension - Reloaded.</article-title>
            <source>Indian Heart J</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>284</fpage>
            <pub-id pub-id-type="pmid">28460781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Akbari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Khorasani-Zadeh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Thiazide Diuretics</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">30422513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Updated hypertension prevalence, awareness, and control rates based on the 2017ACC/AHA high blood pressure guideline.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>758</fpage>
            <page-range>758-765</page-range>
            <pub-id pub-id-type="pmid">31131983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewland</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Yamal</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Piller</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Haywood</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>GM</given-names>
              </name>
              <collab>Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group</collab>
            </person-group>
            <article-title>Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.</article-title>
            <source>JAMA Intern Med</source>
            <year>2016</year>
            <month>Aug</month>
            <day>01</day>
            <volume>176</volume>
            <issue>8</issue>
            <fpage>1085</fpage>
            <page-range>1085-92</page-range>
            <pub-id pub-id-type="pmid">27367818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roush</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Abdelfattah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1507</fpage>
            <page-range>1507-1515</page-range>
            <pub-id pub-id-type="pmid">30251403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kuznia</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>High Blood Pressure in Children and Adolescents.</article-title>
            <source>Am Fam Physician</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>98</volume>
            <issue>8</issue>
            <fpage>486</fpage>
            <page-range>486-494</page-range>
            <pub-id pub-id-type="pmid">30277729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nevoux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dornhoffer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kitahara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Darrouzet</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>International consensus (ICON) on treatment of M&#x000e9;ni&#x000e8;re's disease.</article-title>
            <source>Eur Ann Otorhinolaryngol Head Neck Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>135</volume>
            <issue>1S</issue>
            <fpage>S29</fpage>
            <page-range>S29-S32</page-range>
            <pub-id pub-id-type="pmid">29338942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lohrmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schlatter</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Action of diuretics at the cellular level.</article-title>
            <source>Clin Nephrol</source>
            <year>1992</year>
            <volume>38 Suppl 1</volume>
            <fpage>S64</fpage>
            <page-range>S64-8</page-range>
            <pub-id pub-id-type="pmid">1338305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearle</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Assimos</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Denu-Ciocca</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Matlaga</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Monga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penniston</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Preminger</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Turk</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JR</given-names>
              </name>
              <collab>American Urological Assocation</collab>
            </person-group>
            <article-title>Medical management of kidney stones: AUA guideline.</article-title>
            <source>J Urol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>192</volume>
            <issue>2</issue>
            <fpage>316</fpage>
            <page-range>316-24</page-range>
            <pub-id pub-id-type="pmid">24857648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dineva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uzunova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pavlova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Filipova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalinov</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vekov</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis.</article-title>
            <source>J Hum Hypertens</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>766</fpage>
            <page-range>766-774</page-range>
            <pub-id pub-id-type="pmid">31595024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pareek</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Chandurkar</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Dharmadhikari</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Godbole</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Kshirsagar</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kumbla</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>02</day>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-389</page-range>
            <pub-id pub-id-type="pmid">26821625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roush</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Holford</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Guddati</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.</article-title>
            <source>Hypertension</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>1110</fpage>
            <page-range>1110-7</page-range>
            <pub-id pub-id-type="pmid">22526259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.</article-title>
            <source>Hypertension</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-9</page-range>
            <pub-id pub-id-type="pmid">14638621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derington</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Bress</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Herrick</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zheutlin</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Berchie</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Conroy</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2023</year>
            <month>Jun</month>
            <day>06</day>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e028573</fpage>
            <pub-id pub-id-type="pmid">37158068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1269</fpage>
            <page-range>1269-1324</page-range>
            <pub-id pub-id-type="pmid">29133354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hollenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Warner Stevenson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Storrow</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart&#x000a0;Failure: A Report of the American College of Cardiology Solution Set Oversight Committee.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Oct</month>
            <day>15</day>
            <volume>74</volume>
            <issue>15</issue>
            <fpage>1966</fpage>
            <page-range>1966-2011</page-range>
            <pub-id pub-id-type="pmid">31526538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group</collab>
            <article-title>KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney&#x000a0;Disease.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>99</volume>
            <issue>3S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S87</page-range>
            <pub-id pub-id-type="pmid">33637192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Balmes-Fenwick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>30</day>
            <volume>385</volume>
            <issue>27</issue>
            <fpage>2507</fpage>
            <page-range>2507-2519</page-range>
            <pub-id pub-id-type="pmid">34739197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Chlorthalidone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaelber</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Baker-Smith</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blowey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dionne</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Falkner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leu</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simasek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Urbina</surname>
                <given-names>EM</given-names>
              </name>
              <collab>SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN</collab>
            </person-group>
            <article-title>Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28827377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hung</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Abreu Lanfranco</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Contemporary review of drug-induced pancreatitis: A different perspective.</article-title>
            <source>World J Gastrointest Pathophysiol</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>405</fpage>
            <page-range>405-15</page-range>
            <pub-id pub-id-type="pmid">25400984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ranugha</surname>
                <given-names>PSS</given-names>
              </name>
              <name>
                <surname>Betkerur</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensives in dermatology Part II - Cutaneous adverse reactions to antihypertensives.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2018</year>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-147</page-range>
            <pub-id pub-id-type="pmid">29405133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Salem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fathallah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hmouda</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hyperuricaemia and gout.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>679</fpage>
            <page-range>679-688</page-range>
            <pub-id pub-id-type="pmid">27498351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Thiazide and loop diuretics.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>639</fpage>
            <page-range>639-43</page-range>
            <pub-id pub-id-type="pmid">21896142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vongpatanasin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Giacona</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pittman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moe</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>CCY</given-names>
              </name>
            </person-group>
            <article-title>Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone.</article-title>
            <source>Hypertension</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>80</volume>
            <issue>12</issue>
            <fpage>2611</fpage>
            <page-range>2611-2620</page-range>
            <pub-id pub-id-type="pmid">37846572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Milfred-LaForest</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone?</article-title>
            <source>Cleve Clin J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>82</volume>
            <issue>8</issue>
            <fpage>527</fpage>
            <page-range>527-33</page-range>
            <pub-id pub-id-type="pmid">26270432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57164.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Kuperman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Jaggi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hojnowski-Diaz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fiskio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and consequences of drug allergy alert overrides in a computerized physician order entry system.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>482</fpage>
            <page-range>482-91</page-range>
            <pub-id pub-id-type="pmid">15298998</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
